DNA Link Past Earnings Performance
Past criteria checks 0/6
DNA Link has been growing earnings at an average annual rate of 11.6%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 8% per year.
Key information
11.6%
Earnings growth rate
20.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 8.0% |
| Return on equity | -16.6% |
| Net Margin | -20.4% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How DNA Link makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 21,046 | -4,295 | 8,176 | 19 |
| 31 Dec 23 | 21,949 | -5,596 | 8,574 | 85 |
| 30 Sep 23 | 18,947 | -6,462 | 8,700 | 214 |
| 30 Jun 23 | 18,718 | -5,785 | 8,495 | 45 |
| 31 Mar 23 | 17,427 | -5,631 | 7,741 | 66 |
| 31 Dec 22 | 16,981 | -7,782 | 7,141 | 465 |
| 30 Sep 22 | 19,141 | -7,014 | 9,788 | 518 |
| 30 Jun 22 | 21,999 | -5,786 | 10,207 | 700 |
| 31 Mar 22 | 23,186 | -7,521 | 10,770 | 792 |
| 31 Dec 21 | 22,992 | -5,100 | 10,603 | 539 |
| 30 Sep 21 | 19,730 | -9,621 | 7,432 | 635 |
| 30 Jun 21 | 16,660 | -12,375 | 6,862 | 768 |
| 31 Mar 21 | 15,903 | -13,164 | 6,815 | 660 |
| 31 Dec 20 | 15,286 | -13,067 | 6,798 | 464 |
| 30 Sep 20 | 15,654 | -14,569 | 10,185 | 255 |
| 30 Jun 20 | 16,208 | -13,247 | 10,376 | 129 |
| 31 Mar 20 | 15,333 | -12,616 | 10,201 | 354 |
| 31 Dec 19 | 15,573 | -13,118 | 9,955 | 356 |
| 30 Sep 19 | 14,397 | -5,336 | 6,071 | 360 |
| 30 Jun 19 | 13,331 | -5,713 | 6,071 | 343 |
| 31 Mar 19 | 14,300 | -4,972 | 6,012 | 120 |
| 31 Dec 18 | 14,876 | -3,753 | 6,010 | 104 |
| 30 Sep 18 | 14,860 | -2,550 | 5,735 | 411 |
| 30 Jun 18 | 15,135 | -863 | 5,274 | 404 |
| 31 Mar 18 | 14,819 | -23 | 4,656 | 411 |
| 31 Dec 17 | 14,480 | 338 | 4,076 | 538 |
| 30 Sep 17 | 14,888 | -2,992 | 4,444 | -74 |
| 30 Jun 17 | 14,620 | -5,741 | 5,046 | 599 |
| 31 Mar 17 | 13,206 | -7,324 | 5,016 | 640 |
| 31 Dec 16 | 11,484 | -9,811 | 5,398 | 585 |
| 30 Sep 16 | 10,126 | -12,938 | 5,557 | 1,809 |
| 30 Jun 16 | 8,869 | -11,341 | 4,561 | 1,149 |
| 31 Mar 16 | 9,396 | -9,283 | 4,587 | 974 |
| 31 Dec 15 | 9,420 | -9,054 | 4,171 | 1,029 |
| 30 Sep 15 | 9,028 | -6,018 | 4,200 | 92 |
| 30 Jun 15 | 9,305 | -5,321 | 4,235 | 204 |
| 31 Dec 14 | 8,733 | -4,459 | 3,412 | 194 |
| 30 Sep 13 | 8,030 | -3,785 | 2,341 | 0 |
| 30 Jun 13 | 9,562 | -2,065 | 2,248 | 0 |
Quality Earnings: A127120 is currently unprofitable.
Growing Profit Margin: A127120 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A127120 is unprofitable, but has reduced losses over the past 5 years at a rate of 11.6% per year.
Accelerating Growth: Unable to compare A127120's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A127120 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A127120 has a negative Return on Equity (-16.56%), as it is currently unprofitable.